Thermo Fisher Scientific Inc. (TMO) has demonstrated resilience amid recent market fluctuations. As of January 28, 2025, the stock is trading at $582.96, reflecting a slight decrease of 0.12% from the previous close. Notably, the stock has risen by approximately 3% since early November 2024 and nearly 11% in January 2025.

In its third-quarter report released in October 2024, Thermo Fisher raised the lower end of its annual profit forecast for the third time that year, now expecting earnings per share between $21.35 and $22.07. This adjustment is attributed to strong demand for the company's tools and services used in drug development. The company maintained its annual revenue forecast of $42.4 billion to $43.3 billion.

Thermo Fisher's diversified product range and minimal reliance on National Institutes of Health funding have helped mitigate potential risks associated with changes in the political landscape. Analysts project earnings growth of 5% in 2025, accelerating to 11% by 2026. At current levels, the stock trades at a reasonable multiple compared to rivals, with Wall Street remaining bullish on its prospects.

In January 2025, Thermo Fisher announced that its Olink® Reveal platform was selected for the world's largest human proteome study, underscoring the company's commitment to advancing scientific research. Overall, Thermo Fisher Scientific continues to exhibit strong financial performance and strategic initiatives, reinforcing its position as a leader in the life sciences industry.